Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Blood (2022) 140 (5): 419–437.

https://doi.org/10.1182/blood.2021012057

Published: 2022

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, John P Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Elaine Jaffe, MD, Susan Bates, MD

Blood (2008) 112 (11): 1567.

https://doi.org/10.1182/blood.V112.11.1567.1567

Published: 2008

Journal Articles

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Susan Bates, MD, Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, William Douglas Figg, Sr., PharmD, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRAPC, Mark Kirschbaum, MD, John P. Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Maryalice Stetler- Stevenson, MD, PhD, Alex Ling, MD, Jean Nichols, PhD

Blood (2008) 112 (11): 1568.

https://doi.org/10.1182/blood.V112.11.1568.1568

Published: 2008

Journal Articles

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Larisa Geskin, MD, FAAD, Francine Foss, MD, Madeleine Duvic, MD, David Straus, MD, Steven Horwitz, MD, Jasmine Zain, MD, Timothy Kuzel, MD, Christiane Querfeld, MD, Kim Campbell, PhD, Robert Knobler, MD

Blood (2007) 110 (11): 2561.

https://doi.org/10.1182/blood.V110.11.2561.2561

Published: 2007

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

NARROW

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Email alerts

ASH Publications

American Society of Hematology

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only